Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors

Atypical antipsychotic drugs (APDs) have been hypothesized to show reduced extrapyramidal side effects (EPS) due to their rapid dissociation from the dopamine D2 receptor. However, support for this hypothesis is limited to a relatively small number of observations made across several decades and und...

Full description

Bibliographic Details
Main Authors: Sykes, David A., Moore, Holly, Stott, Lisa, Holliday, Nicholas, Javitch, Jonathan A., Lane, J. Robert, Charlton, Steven J.
Format: Article
Published: Nature Publishing Group 2017
Subjects:
Online Access:https://eprints.nottingham.ac.uk/50603/
_version_ 1848798293910355968
author Sykes, David A.
Moore, Holly
Stott, Lisa
Holliday, Nicholas
Javitch, Jonathan A.
Lane, J. Robert
Charlton, Steven J.
author_facet Sykes, David A.
Moore, Holly
Stott, Lisa
Holliday, Nicholas
Javitch, Jonathan A.
Lane, J. Robert
Charlton, Steven J.
author_sort Sykes, David A.
building Nottingham Research Data Repository
collection Online Access
description Atypical antipsychotic drugs (APDs) have been hypothesized to show reduced extrapyramidal side effects (EPS) due to their rapid dissociation from the dopamine D2 receptor. However, support for this hypothesis is limited to a relatively small number of observations made across several decades and under different experimental conditions. Here we show that association rates, but not dissociation rates, correlate with EPS. We measured the kinetic binding properties of a series of typical and atypical APDs in a novel time-resolved fluorescence resonance energy transfer assay, and correlated these properties with their EPS and prolactin-elevating liabilities at therapeutic doses. EPS are robustly predicted by a rebinding model that considers the microenvironment of postsynaptic D2 receptors and integrates association and dissociation rates to calculate the net rate of reversal of receptor blockade. Thus, optimizing binding kinetics at the D2 receptor may result in APDs with improved therapeutic profile.
first_indexed 2025-11-14T20:17:29Z
format Article
id nottingham-50603
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T20:17:29Z
publishDate 2017
publisher Nature Publishing Group
recordtype eprints
repository_type Digital Repository
spelling nottingham-506032020-05-04T19:10:35Z https://eprints.nottingham.ac.uk/50603/ Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors Sykes, David A. Moore, Holly Stott, Lisa Holliday, Nicholas Javitch, Jonathan A. Lane, J. Robert Charlton, Steven J. Atypical antipsychotic drugs (APDs) have been hypothesized to show reduced extrapyramidal side effects (EPS) due to their rapid dissociation from the dopamine D2 receptor. However, support for this hypothesis is limited to a relatively small number of observations made across several decades and under different experimental conditions. Here we show that association rates, but not dissociation rates, correlate with EPS. We measured the kinetic binding properties of a series of typical and atypical APDs in a novel time-resolved fluorescence resonance energy transfer assay, and correlated these properties with their EPS and prolactin-elevating liabilities at therapeutic doses. EPS are robustly predicted by a rebinding model that considers the microenvironment of postsynaptic D2 receptors and integrates association and dissociation rates to calculate the net rate of reversal of receptor blockade. Thus, optimizing binding kinetics at the D2 receptor may result in APDs with improved therapeutic profile. Nature Publishing Group 2017-10-02 Article PeerReviewed Sykes, David A., Moore, Holly, Stott, Lisa, Holliday, Nicholas, Javitch, Jonathan A., Lane, J. Robert and Charlton, Steven J. (2017) Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nature Communications, 8 (1). 763/1-763/11. ISSN 2041-1723 Neurotransmitters; Receptor pharmacology https://www.nature.com/articles/s41467-017-00716-z doi:10.1038/s41467-017-00716-z doi:10.1038/s41467-017-00716-z
spellingShingle Neurotransmitters; Receptor pharmacology
Sykes, David A.
Moore, Holly
Stott, Lisa
Holliday, Nicholas
Javitch, Jonathan A.
Lane, J. Robert
Charlton, Steven J.
Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors
title Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors
title_full Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors
title_fullStr Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors
title_full_unstemmed Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors
title_short Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors
title_sort extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine d2 receptors
topic Neurotransmitters; Receptor pharmacology
url https://eprints.nottingham.ac.uk/50603/
https://eprints.nottingham.ac.uk/50603/
https://eprints.nottingham.ac.uk/50603/